How Handl Was 'Built To Buy' By UCB
The Inside Story On Gene Therapy Acquisition
UCB has been looking to go deep into the gene therapy space for some time, CSO Dhaval Patel tells Scrip, saying that instead of treating symptoms, "you should be going for a cure."
You may also be interested in...
US regulators refused to accept the file for one of Y-mAbs's neuroblasoma drugs – omburtamab – in October but have given the green light to a second one, naxitamab.
Rather than hitting the acquisition trial, Biogen has taken the licensing route to expand its psychiatric and neurological disorders pipeline.
As well as highlighting Novartis's burgeoning pipeline, the Swiss major's CEO is confident that its biggest earners will continue to growth for the next five years at least.